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Background: This observational community pharmacy-based study aimed to investigate headache 
characteristics and medication use of persons with regular headache presenting for self-medication.  
Methods: Participants (n=1205) completed (i) a questionnaire to assess current headache medication 
and previous physician diagnosis, (ii) the ID Migraine Screener (ID-M) and (iii) the MIDAS 
questionnaire. 
Results: Forty-four % of the study population (n=528) did not have a physician diagnosis of their 
headache, and 225 of them (225/528, 42.6%) were found to be ID-M positive. The most commonly 
used acute headache drugs were paracetamol (used by 62% of the study population), NSAIDs (39%) 
and combination analgesics (36%). Only 12% of patients physician-diagnosed with migraine used 
prophylactic migraine medication, and 25% used triptans. About 24% of our sample (n=292) 
chronically overused acute medication, which was combination analgesic overuse (n=166), simple 
analgesic overuse (n=130), triptan overuse (n=19), ergot overuse (n=6) and opioid overuse (n=5). 
Only 14.5% was ever advised to limit intake frequency of acute headache treatments. 
Conclusions: This study identified underdiagnosis of migraine, low use of migraine prophylaxis and 
triptans, and high prevalence of medication overuse among subjects seeking self-medication for 
regular headache. Community pharmacists have a strategic position in education and referral of 












Headache is a common reason for self-treatment with over-the-counter (OTC) medication. However, 
overuse of acute headache medication through inappropriate self-medication can cause medication-
overuse headache (MOH). Medication-overuse and subsequent MOH is an increasing problem 
worldwide. Epidemiological data suggest that the prevalence of MOH is at least 1% of adults in the 
general population, and up to 30-50% in patients attending tertiary headache centers (1, 2). 
Diagnosis is not always evident, especially because patients often self-treat without consulting a 
physician.  
Community pharmacists could play an important role in early detection and prevention of MOH, by 
monitoring self-medication of headache and educating patients about the maximum intake 
frequency of acute treatments. Before effective pharmacy programs can be designed, observational 
data on the headache characteristics and the drug utilization of individuals seeking self-medication 
for headache are required. To date, literature on this topic is scarce. We found only one paper, 
describing a small observational study (22 participants) that assessed the degree of headache-related 
disability and treatment views of persons purchasing OTC headache products at community 
pharmacies (3). The other pharmacy-based studies published so far did not focus on self-medicating 
customers, but were: a descriptive study on headaches, drug consumption and life habits of migraine 
patients (4), the development and validation of a pharmacy migraine questionnaire to assess 
eligibility for triptan use (5), and an intervention trial evaluating the effects of pharmaceutical care 
for migraine and headache patients (6).  
The present observational community pharmacy-based study aimed to investigate the headache 
characteristics and the medication use of persons with regular headache, defined for this study as 
headache occurring at least once per month, presenting for self-medication. These data should allow 
us to formulate recommendations for improved primary care management of headache. The work 
was reported in preliminary form at the 15th European Federation of Neurological Societies (EFNS) 





This observational study was carried out from December 2009 till May 2010 in 152 randomly selected 
community pharmacies in Belgium. Approval for the study was granted by the Ethics Committees of 
Ghent University Hospital (for Flanders) and CHU Liege (for Wallonia), and all patients gave written 
informed consent.  
Participants 
Pharmacy customers purchasing an OTC analgesic (OTC analgesics available in Belgium: paracetamol, 
acetylsalicylic acid, ibuprofen 200-400 mg, naproxen 200 mg, and caffeine-containing combination 
analgesics) were approached consecutively and asked whether they bought the OTC analgesic for 
headache. In case of a positive answer, they were invited to participate in the study when fulfilling 
the following inclusion criteria: being aged ≥18 years, purchasing the headache medication for 
themselves, and suffering from headache ≥1x/month. From each of the pharmacies, ten patients 
were planned to be recruited. 
Data collection 
Persons who agreed to participate filled out a self-administered questionnaire, collecting the 
following information: age, gender, physician diagnosis of headache (if available), current acute and 
preventive headache medication (prescription and non-prescription) with frequency of use during 
the prior 3 months, and whether they were ever advised to limit intake of acute headache 
medication. A medication overuser was defined as a person overusing acute headache medication in 
terms of treatment days per month (≥10 days/month for ergotamine, triptans, opioids, and 
combination analgesics; ≥15 days/month for paracetamol, ASA, and NSAIDs) during the previous 3 
months, according to the revised criteria of the International Classification of Headache Disorders 
Second Edition (ICHD-IIR) for MOH (7). 
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All participants also completed the ID Migraine Screener (ID-M), a valid and reliable screening 
instrument for migraine in primary care (8), and the Migraine Disability Assessment (MIDAS) 
questionnaire (9-11). The MIDAS consists of five scored questions on headache-related disability and 
two additional unscored questions on headache frequency (“On how many days in the last 3 months 
did you have any headache [if a headache lasted more than 1 day, count each day]?”) and pain 
intensity (“On a scale from 0 to 10, on average how painful were these headaches?”, where 0 = no 
pain at all, and 10 = pain as bad as it can be). The MIDAS score is classified into four grades of 
severity: little or no disability (grade I, MIDAS score 0-5), mildly limiting disability (grade II, MIDAS 
score 6-10), moderately limiting disability (grade III, MIDAS score 11-20), and severely limiting 
disability (grade IV, MIDAS score >20).  
Data analysis 
Statistical data analysis was performed using SPSS 17.0 for Windows (SPSS Inc, Chicago, IL, USA). 
First, headache characteristics and medication use were described for the entire study population. 
Second, extra analyses were performed on a specific subgroup of interest, i.e. medication overusers. 
To compare subgroup results, we used Pearson’s chi square tests (for categorical data) and Mann-
Whitney U tests (for ordinal data [MIDAS grade, pain intensity] and for non-normally distributed 
continuous data [headache frequency]). P-values of <0.05 were considered significant. 
 
RESULTS 
The participant recruitment process is summarized in Figure 1. About two thirds (3839/5791) of the 
pharmacy customers purchasing an OTC analgesic bought the product for headache. Among the 2042 
individuals who matched the inclusion criteria, 837 (41.0%) refused to participate in the study for 
several reasons: no time (348/837; 41.6%), no interest (306/837; 36.6%), deprivation of privacy 
(69/837; 8.2%), and other reasons (114/837; 13.6%).  
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Overall, 1205 individuals agreed to participate in the survey: 983 (81.6%) were women and 222 
(18.4%) were men. The mean age of the study population was 46.3 years (range 18-88). Seventy-nine 
(6.6%) of the respondents were aged under 25 years, 351 (29.1%) were between 25 and 40 years, 
482 (40.0%) were between 41 and 55 years, 207 (17.2%) were between 56 and 70 years, and 86 
(7.1%) were aged over 70 years.   
Headache characteristics 
Fifty-six % of the participants (n=677) reported a physician diagnosis of headache, mainly migraine 
and tension-type headache (TTH) (Table 1). Seventy-eight % of them (530/677) scored positive on the 
ID-M, the physician diagnoses of these individuals were: migraine (n=383), TTH (n=101), patient 
failed to remember diagnosis (n=36), cluster headache (n=7), MOH (n=2) and headache as side effect 
of oral progesterone use (n=1). Forty-four % of the study population (n=528) did not have a physician 
diagnosis of their headache, and 225 of them (225/528, 42.6%) were found to be ID-M positive.  
Almost 60% of participants reported a MIDAS score ≤10, indicating no to mildly limiting disability 
(grade I-II) (Table 2). About 40% had MIDAS grade III (moderately limiting disability) or IV (severely 
limiting disability). The median headache pain severity was 6, with most patients rating pain between 
5 and 8 on a 0-10 scale. Participants reported a median of 12 headache days in the last 3 months 
(Table 2).    
Medication use 
The median number of acute headache drugs per patient was 2 (range 1-6). About one fifth of 
participants consumed 3 or more different acute headache treatments. About 73% (881/1205) only 
used OTC medication, and 27% used OTC as well as prescription drugs. The most commonly used 
acute medications are shown in Table 3. One-quarter of the patients physician-diagnosed with 
migraine currently used triptans (106/426), and about 12% used prophylactic migraine medication 
(49/426): propranolol (n=21), topiramate (n=16), amitriptyline (n=4), flunarizine (n=4), bisoprolol 
(n=4), riboflavin (n=3), valproate (n=2), pizotifen (n=1), losartan (n=1) and oxeterone (n=1). The 
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triptan and prophylaxis use by migraine patients, as a function of MIDAS grade, are displayed in 
Figure 2. 
Only 14.5% was ever advised to limit intake frequency of acute headache treatments. About one 
quarter of our sample (n=292, 24.2%) chronically overused acute medication, which was combination 
analgesic overuse (n=166), simple analgesic overuse (n=130), triptan overuse (n=19), ergot overuse 
(n=6) and opioid overuse (n=5).  
Characterisation of medication overusers  
Three-quarters of the medication overusers (220/292) had a physician diagnosis of headache: 
migraine (123/220; 55.9%), TTH (68/220; 30.9%), MOH (4/220; 1.8%) and cluster headache (4/220; 
1.8%). Some patients failed to remember the diagnosis (21/220; 9.5%). Of the 4 overusers with 
cluster headache, 2 were triptan overusers and 2 were simple analgesic and/or combination 
analgesic overusers. About 70% of the migraineurs (87/123) had moderate or severe migraine 
(MIDAS grade III or IV), and only 13 of them (14.9%) used preventive medication and 27 (31.0%) used 
triptans. Based on the ID-M, migraine was likely in a substantial number of TTH patients (42/68; 
61.8%). Of the patients without physician diagnosis, almost half (35/72) was found to be ID-M 
positive.  
With respect to drug consumption, medication overusers were more likely to use 3 or more different 
acute headache drugs than non-overusers (Table 4). There were significantly less users of 
paracetamol and NSAIDs, and significantly more users of codeine-containing combination analgesics, 
caffeine-containing combination analgesics, triptans, ergots and opioids among medication overusers 
than among non-overusers. Overusers also reported higher headache-related disability (i.e., MIDAS 
grade) (p<0.001), more frequent headaches (p<0.001) and higher pain intensity (p<0.001), compared 
to non-overusers (Table 4). Remarkably, 39% of overusers had <30 days of headache in the past 3 
months, but used acute headache drugs for ≥10 days/month (for triptans, ergots, opioids and 





This observational survey provides information about the characteristics and the medication 
consumption of pharmacy customers seeking self-medication for regular headache (defined for this 
study as headache occurring at least once per month). Headache showed to be an important reason 
for OTC analgesic purchase, as two thirds of the dispensed OTC analgesics were used to treat 
headache. Our study identified three main problems with headache management: (i) migraine is 
underdiagnosed, (ii) patients with a physician diagnosis of migraine may receive suboptimal 
treatment, and (iii) the prevalence of medication overuse is high. 
Almost half of individuals without physician diagnosis of migraine scored positive on the ID-M. As the 
ID-M is a screening instrument with high positive predictive value (8), we can assume that the 
majority of them will indeed suffer from migraine. This is in line with previous research, showing that 
migraine is underdiagnosed in primary care (12-14). Most of our participants with possible migraine 
did not have a physician diagnosis (suggesting that persons with migraine complaints either do not 
consult a physician or do consult a physician but do not receive a diagnosis) or were wrongly 
diagnosed as having TTH. Such underrecognition of migraine might prompt inappropriate self-
medication practices. Indeed, about one quarter of the possibly undiagnosed migraine patients in our 
study met the ICHD-IIR criteria of medication overuse. Concerning the ID-M, it is noteworthy that its 
sensitivity is 81%, thus not all participants with a physician diagnosis of migraine scored ID-M 
positive. Its specificity is 75% which led to cluster headache patients scoring positive (8).  
Only 12% of the physician-diagnosed migraine patients in this study was prescribed preventive 
medication. This percentage is similar to that found in previous studies conducted in the U.S. (12%) 
(15), Italy (14%) (16), The Netherlands (8%) (17), and France (6%) (18). Migraine prophylaxis is 
indicated for patients with frequent disabling attacks (19), and it has been proven effective in 
reducing resource utilization (20) and in improving quality of life and activity limitations (21). 
Nevertheless, only 8% of the MIDAS grade III migraine patients in this study and only 17% of the 
MIDAS grade IV migraine patients were prescribed preventive therapy. It should be noted, however, 
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that this study only looked at current use of prophylaxis. Patients may already have used prophylaxis 
in the past but terminated treatment due to adverse effects, insufficient therapeutic effect or other 
reasons. Another finding indicating possible suboptimal migraine treatment is the fact that only one 
quarter of the migraineurs with MIDAS III-IV used triptans. Triptans may have significant effects on 
quality of life of migraine patients and on migraine-related costs (22-26). The low use of triptans in 
this study could be related to the stepped-care approach used in Belgium, whereby migraine-specific 
therapy may be delayed far more than in stratified care. In addition, patients may not follow-up with 
their physician when the initial treatment step (e.g., simple analgesic) fails and instead they may 
lapse from medical care (27, 28). As mentioned above for prophylaxis use, it should be borne in mind 
that the non-triptan users in this study may have tried triptans in the past but stopped. It is also 
relevant to note that triptans are available only by prescription in Belgium, in contrast to the 
neighbouring countries UK and Germany where some are OTC available (29).  
Another important finding is the high prevalence of medication overuse (24%). However, less than 
1% of the study population had a physician diagnosis of MOH. Our data suggest that consumers of 
three or more different acute headache drugs are more likely to overuse. A substantial proportion of 
overusers did not have chronic headache, meaning that they also used the analgesics for other pain 
conditions than headache (unfortunately, we did not record for what other conditions). However, 
these patients are also at risk for developing MOH, due to their regular headache in combination 
with medication overuse. We also found that patient education about limits on the use of analgesics 
is poorly implemented in Belgian practice, as only 15% ever received such advice.  
Based on the results of this study, recommendations for improved community pharmacy 
management of headache complaints can be formulated. Firstly, pharmacists are in a unique position 
to improve migraine recognition in primary care. Pharmacy customers seeking self-medication for 
regular headache could be asked to complete the ID-M, and if positive, referral to a general 
practitioner should be made. In this way, the number of headache patients seeking medical care 
could be increased, as lack of consultation is a major contributing factor to the underdiagnosis of 
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migraine (30). From a practical point of view, the ID-M showed to be an easy to use method for 
migraine screening in the community pharmacy setting. Secondly, pharmacists could play an 
important role in prevention and early detection of medication overuse and subsequent MOH. The 
most important preventive measure is proper instruction and appropriate surveillance of patients 
(31). Patients may often be unaware of the risk of the developing rebound headache when 
frequently using analgesics. Therefore, simple pharmacist advice regarding the maximum intake 
frequency (routinely provided at dispensation of acute headache medication) seems useful. Provided 
that they keep records of OTC medication dispensing, pharmacists are also well-placed to alertly 
follow up individuals regularly purchasing OTC products for headaches. At suspicion of medication 
overuse, patients should be informed about the possible link between their chronic headache and 
their medication use, and encouraged to consult a physician. Previous studies conducted in the 
hospital setting have proven that simple advice is effective in both prevention and treatment of MOH 
(32, 33). Thirdly, migraine patients with frequent disabling attacks who are not experiencing 
sufficient pain relief with their current treatment should be referred to a physician for other 
therapeutic options (triptans and/or preventive treatment; available by prescription only in Belgium).  
This study has some limitations. Physician diagnosis and medication use were based on self-
reporting, which holds the risk of recall bias. Another limitation is that this study only screened for 
medication overuse, but did not make MOH diagnosis. Finally, the Dutch versions of the ID-M and the 
MIDAS have not been formally validated. However, previous validation studies on translations of 
both instruments did not report problems (34-37). The main strength is that this is the first extensive 
survey providing data on the headache complaints and drug utilization of self-medicating individuals 
in the community pharmacy setting. Furthermore, our study design and setting aimed to minimize 
the risk of selection bias: (i) the community pharmacies participating in this study were randomly 
selected, and each of them recruited a similar number of participants, (ii) pharmacy customers were 
randomly recruited (i.e., consecutively), and (iii) in Belgium, the sale of OTC medicines is limited to 
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pharmacies, meaning that we sampled from the entire population of persons with self-medication 
intentions.  
In conclusion, this study identified underdiagnosis of migraine, low use of migraine prophylaxis and 
triptans, and underdiagnosis of MOH among subjects seeking self-medication for regular headache. 
Community pharmacists have a strategic position in education and referral of these self-medicating 
headache patients.  
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TABLES AND FIGURES: captions 
 
 
Table 1:  Physician diagnosis of headache. 
 
Table 2:   Headache-related disability, frequency of headaches and pain intensity (based on the  
MIDAS questionnaire). 
 
Table 3:  Acute headache medication used by the study population. 
 
Table 4: Acute headache medication use and headache-related disability, frequency of headaches  
and pain intensity of medication overusers vs non-overusers. 
 
Figure 1:  Flow scheme of the participant recruitment process. 
 
Figure 2: Prophylaxis and triptan use by patients with a physician diagnosis of migraine, as a function 
of MIDAS grade. 
 
